Literature DB >> 24710647

Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.

Sophie M Lehnerer1, Urban M Fietzek, Michael Messner, Andres O Ceballos-Baumann.   

Abstract

Continuous jejunal levodopa infusion is an increasingly used therapy option in patients with Parkinson's disease who experience severe fluctuations from oral levodopa. In a number of recent reports polyneuropathy in patients receiving jejunal levodopa infusion was referenced to cobalamin (vitamin B12) deficiency. We describe one of three cases from our hospital with severe subacute polyneuropathy that developed during jejunal levodopa infusion, and occurred despite vitamin substitution therapy and normal vitamin B12 and holotranscobalamin serum levels.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24710647     DOI: 10.1007/s00702-014-1204-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  18 in total

Review 1.  Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert.

Authors:  Diego Santos-García; Raúl de la Fuente-Fernández; Francesc Valldeoriola; Antonio Palasí; Fátima Carrillo; Mónica Grande; Pablo Mir; Oriol De Fabregues; Jordi Casanova
Journal:  J Neurol       Date:  2012-01-24       Impact factor: 4.849

Review 2.  Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.

Authors:  Thomas Müller
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

3.  Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.

Authors:  Roberto Ceravolo; Giovanni Cossu; Monica Bandettini di Poggio; Lucio Santoro; Paolo Barone; Maurizio Zibetti; Daniela Frosini; Valentina Nicoletti; Fiore Manganelli; Rosa Iodice; Marina Picillo; Aristide Merola; Leonardo Lopiano; Alessandra Paribello; Davide Manca; Maurizio Melis; Roberta Marchese; Paolo Borelli; Alessandra Mereu; Paolo Contu; Giovanni Abbruzzese; Ubaldo Bonuccelli
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

4.  Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.

Authors:  Davide Manca; Giovanni Cossu; Daniela Murgia; Andrea Molari; Paola Ferrigno; Emanuele Marcia; Maurizio Melis
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

Review 5.  Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties.

Authors:  Federico Cacciapuoti
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

6.  Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.

Authors:  Anne Marthe Meppelink; Rickard Nyman; Teus van Laar; Martje Drent; Ted Prins; Klaus Leonhard Leenders
Journal:  Mov Disord       Date:  2010-10-19       Impact factor: 10.338

7.  Malnutritional neuropathy under intestinal levodopa infusion.

Authors:  Fabian Klostermann; Constanze Jugel; Thomas Müller; Frank Marzinzik
Journal:  J Neural Transm (Vienna)       Date:  2011-07-24       Impact factor: 3.575

Review 8.  Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery.

Authors:  Thomas Müller; Teus van Laar; David R Cornblath; Per Odin; Fabian Klostermann; Francisco J Grandas; Georg Ebersbach; Peter P Urban; Francesc Valldeoriola; Angelo Antonini
Journal:  Parkinsonism Relat Disord       Date:  2013-02-27       Impact factor: 4.891

9.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

Authors:  C Warren Olanow; Karl Kieburtz; Per Odin; Alberto J Espay; David G Standaert; Hubert H Fernandez; Arvydas Vanagunas; Ahmed A Othman; Katherine L Widnell; Weining Z Robieson; Yili Pritchett; Krai Chatamra; Janet Benesh; Robert A Lenz; Angelo Antonini
Journal:  Lancet Neurol       Date:  2013-12-20       Impact factor: 44.182

10.  Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs.

Authors:  Constanze Jugel; Felicitas Ehlen; Birol Taskin; Frank Marzinzik; Thomas Müller; Fabian Klostermann
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more
  3 in total

Review 1.  Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.

Authors:  Johan Virhammar; Dag Nyholm
Journal:  Ther Adv Neurol Disord       Date:  2016-12-01       Impact factor: 6.570

Review 2.  Novel Levodopa Formulations for Parkinson's Disease.

Authors:  Maria Eliza Freitas; Marta Ruiz-Lopez; Susan H Fox
Journal:  CNS Drugs       Date:  2016-11       Impact factor: 5.749

Review 3.  Levodopa-Induced Neuropathy: A Systematic Review.

Authors:  Alberto Romagnolo; Aristide Merola; Carlo Alberto Artusi; Mario Giorgio Rizzone; Maurizio Zibetti; Leonardo Lopiano
Journal:  Mov Disord Clin Pract       Date:  2018-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.